Outlook Therapeutics OTLK - オプションチェーン

Outlook Therapeutics Inc ([symbol]) オプションチェーン

オプションコール

行使価格	前回の価格	中間価格	建玉	最終取引
0.50	1.10	1.10	29	-
1.00	0.65	0.65	548	-
1.50	0.40	0.40	1,448	-
2.00	0.25	0.25	556	-
2.50	0.13	0.13	5,100	-
5.00	0.05	0.05	289	-
7.50	0.05	0.05	49	-

個人投資家向けのプロ仕様のツール。

プレミアム

オプションプット

行使価格	前回の価格	中間価格	建玉	最終取引
0.50	0.02	0.02	866	-
1.00	0.10	0.10	481	-
1.50	0.30	0.30	821	-
2.00	0.60	0.60	2	-
2.50	0.00	0.00	0	-
5.00	0.00	0.00	0	-
7.50	0.00	0.00	0	-

銘柄コード	株価	出来高
ADTXAditxt Inc	US$ 0.01 (127.27%)	5.38B
LNKSLinkers Industries Ltd	US$ 2.6509 (65.68%)	69.88M
CASTFreeCast Inc	US$ 8.0101 (55.54%)	113.02M
CDTCDT Equity Inc	US$ 1.0101 (45.76%)	249.47M
APWCAsia Pacific Wire and Cable Corporation Ltd	US$ 2.02 (45.32%)	48.09M
INLFINLIF Limited	US$ 0.1533 (-64.95%)	131.52M
SNBRSleep Number Corporation	US$ 0.2152 (-44.82%)	52.75M
YYGHYY Group Holding Ltd	US$ 0.0791 (-38.63%)	82.04M
LABTLakewood-Amedex Biotherapeutics Inc	US$ 0.3852 (-36.03%)	1.83M
EHGOEshallgo Inc	US$ 1.895 (-34.43%)	2.2M
ADTXAditxt Inc	US$ 0.01 (127.27%)	5.38B
GDCGD Culture Group Ltd	US$ 0.0177 (-16.90%)	931.09M
SPCXSpace Exploration Technologies Corporation	US$ 185.00 (-3.56%)	272.29M
MRVLMarvell Technology Inc	US$ 310.58 (7.27%)	251.21M
CDTCDT Equity Inc	US$ 1.0101 (45.76%)	249.47M

銘柄コード

株価

出来高

ADTXAditxt Inc

US$ 0.01

(127.27%)

5.38B

GDCGD Culture Group Ltd

US$ 0.0177

(-16.90%)

931.09M

SPCXSpace Exploration Technologies Corporation

US$ 185.00

(-3.56%)

272.29M

MRVLMarvell Technology Inc

US$ 310.58

(7.27%)

251.21M

CDTCDT Equity Inc

US$ 1.0101

(45.76%)

249.47M

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

June 16, 2026

• Outlook Therapeutics said it has already started pre-launch activities.

• The FDA refused to approve LYTENAVA in December, but later determined that no additional clinical trials would be required following the company's appeal.

• If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab.

Shares of Outlook Therapeutics, Inc. (OTLK) jumped 28% on Tuesday after the company announced today that the U.S. Food and Drug Administration has accepted its resubmitted biologics license application for LYTENAVA as a treatment for wet age-related macular degeneration (wet AMD).

The agency will now decide whether to approve the drug by July 29, 2026. The company has already begun pre-launch activities.

See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox

OTLK's Long Regulatory Road
The FDA had refused to approve the drug in December. Outlook Therapeutics appealed the decision, and the FDA Office of New Drugs subsequently concluded that no additional trials are required, stating that substantial evidence of effectiveness has already been established. The agency instead directed the review division to focus on final product labeling, and the company resubmitted its application earlier this month.

The company's original application was accepted by the FDA in October 2022. In August 2023, the agency issued its first letter refusing approval, citing Chemistry, Manufacturing and Controls (CMC) deficiencies, observations from pre-approval manufacturing inspections, and insufficient substantial evidence of effectiveness.

Outlook responded by addressing the manufacturing issues and, in early 2025, resubmitted the application. The FDA accepted it in April 2025, but the agency denied its approval again in late 2025, this time focusing on a perceived lack of confirmatory efficacy evidence and recommending additional data.

If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab, an antibody medication used to treat various solid tumors and specific eye diseases. The product is already approved in the European Union and the United Kingdom for wet AMD, a severe, progressive eye condition where abnormal blood vessels grow uncontrollably under the retina. These fragile vessels leak fluid and blood, causing rapid and often irreversible central vision loss if left untreated.

How Did OTLK Retail Traders React?
On Stocktwits, retail sentiment around OTLK stayed within the 'extremely bullish' territory over the past 24 hours, while message volume increased from 'high' to 'extremely high' levels.

A Stocktwits user highlighted that the company has already begun pre-launch activities.

Others voiced hopes for a major rally on approval for the drug.

According to Koyfin data, two of the four analysts covering OTLK rate it 'Buy,' while the other two rate it a 'Hold.' The 12-month average price target on the stock is $5.50, representing a potential upside of 374% from the stock's last close.

OTLK stock has gained 126% this year.

Link article

$OTLK 🗞️